Patient info Open main menu

Yointy 625 mg hard capsules – patient leaflet, side effects, dosage

Last updated: · Text from the MHRA, as of · About this document

Medicine strength:
625 mg
Contains active substance:

Patient leaflet - Yointy 625 mg hard capsules

1. What Yointy is and what it is used for

Yointy belongs to the group of medicines called other antiinflammatory and anti-rheumatic agents, non-steroids.

Yointy contains the active substance glucosamine.

Yointy is used to relieve the symptoms in mild to moderate osteoarthritis of the knee.

2. What you need to know before you take Yointy

Do not take Yointy

  • if you are allergic to glucosamine or to any of the other ingredients of this medicine (listed in section 6).
  • if you are allergic to shellfish, as glucosamine is obtained from shellfish.

Warnings and precautions

Talk to your doctor or pharmacist before taking Yointy

  • if your suffer from impaired glucose tolerance. More frequent controls of your blood glucose levels may be necessary when starting treatment with Yointy.
  • if you have a known risk factor for cardiovascular disease, since raised cholesterol has been observed in a few cases in patients treated with glucosamine.
  • if you suffer from asthma. When starting on glucosamine, you should be aware of potential worsening of symptoms.
  • if you have problems with your kidney or liver, since no studies with glucosamine have been performed in such patients dose recommendations cannot be given.

Other medicines and Yointy

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription.

Caution should be exercised if Yointy has to be combined with other medicines, especially with:

  • Some types of medicines used to prevent blood clotting (e.g. warfarin, dicoumarol, phenprocoumon, acenocoumarol and fluidione). The effect of these medicines may be stronger when used with glucosamine. Patients treated with such combinations should therefore be monitored extra carefully when initiating or ending glucosamine therapy.
  • Tetracyclines (antibacterials used against infection).

Yointy with food and drink

Yointy could be taken with food and drink before, during or after a meal.

Pregnancy, breast-feeding and fertility

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.

Yointy should not be used during pregnancy.

The use of Yointy is not recommended during breast-feeding.

Driving and using machines

No studies on the effects on the ability to drive and use machines have been performed. If you experience dizziness or drowsiness from the capsules, you should not drive or operate machinery.

3. How to take Yointy

Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.

The usual dose is 2 capsules once daily (1250 mg glucosamine).

Swallow the hard capsules together with some water. Do not chew the capsules.

Glucosamine is not indicated for the treatment of acute pain. Relief of symptoms (especially pain relief) may not happen for several weeks and in sometimes even longer. If there is no benefit after 2-3 months, please tell your doctor.

Use in children and adolescents

Yointy is not recommended for use in children below 18 years.

If you take more Yointy than you should

If you have taken more capsules than you should, you may experience headache, vertigo, disorientation, pain in joints, nausea, vomiting or diarrhoea, although it is possible you may not experinece any symptoms. In any case, inform your doctor.

If you forget to take Yointy

If you forget to take a dose, just take the next dose as nomal. Do no take a double dose to make up for a forgotten dose.

If you stop taking Yointy

Keep taking this medicine until your doctor tells you to stop. Do not stop taking it just because you feel better. If you stop taking the medicine, your condition may re-occur.

If you have any further questions on the use of this product, ask your doctor or pharmacist.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them. These are usually mild and transient.

Serious side effects

You should stop taking glucosamine and tell your doctor immediately or go to the nearest hospital immediately if you experience any of the following symptoms as these symptoms may indicate you are suffering a severe allergic reaction to this medicine:

  • swelling of the face, tongue, throat
  • difficulty in swallowing or breathing
  • rash or hives

Other side effects

Common: may affect up to 1 in 10 people

Headache, tiredness, nausea, abdominal pain, indigestion, diarrhoea, constipation.

Uncommon: may affect up to 1 in 100 people

Rash, itching, flushing

Not known: frequency cannot be estimated from the available data

Vomiting, urticaria, dizziness, swelling of the feet or ankles, angioedema. Aggravation of pre-existing asthma, blood glucose control worsened in diabetic patients.

Elevated cholesterol levels have been also reported. It is not possible to determine whether these events were directly related to glucosamine.

Reporting of side effects

If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or serach for MHRA Yellow Card in the Google Play or Apple App Store.

By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store Yointy

Keep this medicine out of the sight and reach of children.

Do not store above 30°C. Store in the original package to protect from moisture.

Do not use Yointy after the expiry date which is stated on the carton after EXP. The expiry date refers to the last day of that month.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What Yointy contains

  • The active substance is glucosamine. Each capsule contains 625 mg of glucosamine (equivalent to 750 mg of glucosamine hydrochloride).
  • The other ingredient is magnesium stearate.

    Capsule composition: gelatin, red iron oxide (E172), titanium dioxide (E171), black iron oxide (E172).

What Yointy looks like and contents of the pack

Yointy are brown coloured hard gelatine capsules.

Yointy is delivered in a cardboard box containing 10, 60 and 180 capsules in blister packs.

Not all pack sizes may be marketed.

Marketing Authorisation Holder

LABORATORIO REIG JOFRE S.A.

Gran Capitán 10

08970 Sant Joan Despí (Barcelona)

Spain

Manufacturer

NOUCOR HEALTH, S.A.

Avda. Camí Reial 51-57

08184 Palau-solità i Plegamans (Barcelona)

Spain

This leaflet was last revised in January 2023.

About this document

Source: MHRA - Medicines and Healthcare products Regulatory Agency (products.mhra.gov.uk) · Marketing authorisation: PL 25174/0035

Last revision stated in the text: January 2023 · MHRA data as of 13 October 2026

Found a mistake? Tell us on the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Facts about Yointy 625 mg hard capsules

Active substance Glucosamine hydrochloride
Strength 625 mg
Pharmaceutical form Brown coloured hard gelatine capsules of size nº0EL.
Excipients Magnesium stearate., Gelatin, Red iron oxide (E172), Titanium dioxide (E171), Black iron oxide (E172)
Shelf life 3 years
Storage Do not store above 30°C. Store in the original package in order to protect from moisture.
Drug group (ATC) Other antiinflammatory and antirheumatic agents, non-steroids
Marketing authorisation PL 25174/0035 (first authorised 28 February 2012)
Marketing authorisation holder LABORATORIO REIG JOFRE S.A.

Sources: the MHRA product information (products.mhra.gov.uk). Contains public sector information licensed under the Open Government Licence v3.0.